Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBD4059 in Stable Coronary Artery Disease
NCT06717074Phase 2Completed
- Sponsor
- Ribocure Pharmaceuticals AB
- Start
- Aug 2024
- Primary completion
- Apr 2026
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of RBD4059 in coronary artery disease (CAD), sponsored by Ribocure Pharmaceuticals AB. Started Aug 2024; status: completed.
02
Drugs
RBD4059
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06717074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06717074.